What Fueled The Previous Growth In The Drug And Gene Delivery Devices Market?
The drug and gene delivery devices market has seen considerable growth due to a variety of factors.
• The market size for drug and gene delivery devices has witnessed robust growth in the recent past. The market, which stood at $0.61 billion in 2024, is projected to reach $0.67 billion in 2025, reflecting a compound annual growth rate (CAGR) of 9.0%.
The expansion during the historic period is credited to the development of healthcare infrastructure, the broadening of personalized gene therapy programs, an amplified emphasis on preventive healthcare, the rising focus on rare and orphan diseases, and an uptick in public consciousness regarding health and treatment choices.
How Does the Forecast Look for the Drug And Gene Delivery Devices Market?
The drug and gene delivery devices market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the market for drug and gene delivery devices is anticipated to witness a substantial increase, expanding to $0.93 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%.
This projected growth can be associated with the escalating prevalence of chronic diseases, the rising need for personalized medicine, heightened awareness and acceptance of gene therapy, demand for non-invasive and minimally invasive procedures, and the increasing appreciation of direct-to-patient delivery models. Looking ahead, the market trend is likely to feature breakthroughs in biotechnology and genetic engineering, advancements in drug delivery system technologies, an increase in research and development funding, the creation of innovative delivery platforms, and advancements in diagnostic technologies.
What Are The Leading Drivers Of Growth In The Drug And Gene Delivery Devices Market?
The drug and gene delivery devices market is set to expand, fueled by the growing usage of gene therapy. Gene therapy, a medical method that modifies a patient's genetic material to treat or fight against diseases, is gaining traction owing to its potential to address the fundamental causes of genetic disorders and chronic diseases, providing transformative treatments where traditional approaches are not effective. Precise targeting and controlled release of therapeutic genes are made possible with the aid of drug and gene delivery devices, improving the effectiveness of treatment. For instance, the National Centre for Biotechnology Information, an American resource for the scientific research community, has projected that patients undergoing gene therapies will rise from 16,244 in 2020 to an estimated 94,696 in 2025. As a result, the upswing in the adoption of gene therapy is accelerating the growth of the drug and gene delivery devices market.
How Are The Segments Defined Within The Global Drug And Gene Delivery Devices Market?
The drug and gene delivery devicesmarket covered in this report is segmented –
1) By Vector: Viral, Non-viral
2) By Method: In Situ, Ex Vivo
3) By Route Of Administration: Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal, Topical
Subsegments:
1) By Viral: Adenovirus Vectors, Lentivirus Vectors, Adeno-Associated Virus (AAV) Vectors, Herpes Simplex Virus (HSV) Vectors, Retrovirus Vectors, Baculovirus Vectors, Vaccinia Virus Vectors, Sendai Virus Vectors
2) By Non-Viral: Lipid Nanoparticles (LNP), Polymeric Nanoparticles, Liposomes, Dendrimers, Naked DNA/RNA Delivery, Electroporation-Based Delivery Systems, Nanoparticle-Based Delivery Systems, Polymer Micelles And Hydrogels.
Pre-Book The Drug And Gene Delivery Devices Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing The Drug And Gene Delivery Devices Market?
Prominent firms in the drug and gene delivery devices sector are concentrating their efforts on the advancement of superior products, such as artificial intelligence (AI), to strengthen their position in the market. The use of AI in drug delivery involves the application of AI methodologies and techniques to enhance the precision, efficiency, and effectiveness of drug delivery mechanisms. For instance, Envoya Inc., an American company that develops polymer-based nanoparticles for targeted delivery, unveiled an innovative gene therapy drug delivery platform in December 2023. This revolutionary platform merges biopolymer-nanoparticles with AI to tackle significant setbacks in the existing gene therapy technologies, such as viral vectors and lipid nanoparticles. The system is designed to surpass the constraints bound to current gene therapy delivery technologies, centered around safety concerns, limited payload capabilities, and restricted tissue targeting.
Who Are the Key Players In The Drug And Gene Delivery Devices Market?
Major companies operating in the drug and gene delivery devices market are:
• Merck & Co. Inc.
• AbbVie Inc.
• Bayer AG
• AstraZeneca plc
• Medtronic plc
• Amgen Inc.
• Moderna Inc.
• Biogen Inc.
• Sarepta Therapeutics Inc.
• SCIEX
• Halozyme Therapeutics Inc.
• ViiV Healthcare Limited
• Uniqure NV
• Cytokinetics Inc.
• Prothena Corporation plc
• Intellia Therapeutics Inc.
• Voyager Therapeutics Inc.
• sfm medical devices GmbH
• Inovio Pharmaceuticals Inc.
• GenSight Biologics S.A.
• CRISPR Therapeutics
What Is The Most Dominant Region In The Drug And Gene Delivery Devices Market?
North America was the largest region in the drug and gene delivery devices market in 2024. The regions covered in the drug and gene delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
